在体内测试阿尔茨海默病的淀粉样蛋白假说。 - Suppr

Suppr

超能文献

Testing the amyloid hypothesis of Alzheimer's disease in vivo.

作者信息

Gandy Sam

出版信息

Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26.

DOI:10.1016/S1474-4422(10)70055-7

PMID:20189880

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3274723/

Abstract

摘要

相似文献

Testing the amyloid hypothesis of Alzheimer's disease in vivo.

Lancet Neurol. 2010 Apr;9(4):333-5. doi: 10.1016/S1474-4422(10)70055-7. Epub 2010 Feb 26.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer's Disease Trials of Bapineuzumab.

J Alzheimers Dis. 2016 May 3;53(2):535-46. doi: 10.3233/JAD-151065.

Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab.

Neurology. 2018 Mar 6;90(10):e877-e886. doi: 10.1212/WNL.0000000000005060. Epub 2018 Feb 2.

LRP-1 polymorphism is associated with global and regional amyloid load in Alzheimer's Disease in humans in-vivo.

Neuroimage Clin. 2014 Feb 5;4:411-6. doi: 10.1016/j.nicl.2014.01.016. eCollection 2014.

Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).

Alzheimers Res Ther. 2018 Sep 19;10(1):96. doi: 10.1186/s13195-018-0424-5.

Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease.

Alzheimers Dement. 2017 Nov;13(11):1197-1206. doi: 10.1016/j.jalz.2017.03.008. Epub 2017 May 11.

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.

Clinical Aspects of Alzheimer's Disease.

Adv Neurobiol. 2017;15:31-53. doi: 10.1007/978-3-319-57193-5_2.

Memory performance-related dynamic brain connectivity indicates pathological burden and genetic risk for Alzheimer's disease.

Alzheimers Res Ther. 2017 Mar 31;9(1):24. doi: 10.1186/s13195-017-0249-7.

引用本文的文献

Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Annu Rev Med. 2013;64:367-83. doi: 10.1146/annurev-med-092611-084441.

Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.

PLoS One. 2012;7(11):e50317. doi: 10.1371/journal.pone.0050317. Epub 2012 Nov 27.

Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

J Neurosci. 2012 Feb 22;32(8):2696-702. doi: 10.1523/JNEUROSCI.1676-11.2012.

Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.

Expert Rev Med Devices. 2012 Jan;9(1):71-83. doi: 10.1586/erd.11.64.

A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.

J Neurochem. 2011 Oct;119(1):189-201. doi: 10.1111/j.1471-4159.2011.07389.x. Epub 2011 Aug 22.

New pathway links γ-secretase to inflammation and memory while sparing notch.

Ann Neurol. 2011 Jan;69(1):5-7. doi: 10.1002/ana.22310.

本文引用的文献

Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.

Dokl Biochem Biophys. 2009 Sep-Oct;428:235-8. doi: 10.1134/s1607672909050032.

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Lancet Neurol. 2010 Apr;9(4):363-72. doi: 10.1016/S1474-4422(10)70043-0. Epub 2010 Feb 26.

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219.

Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.

Mt Sinai J Med. 2010 Jan-Feb;77(1):43-9. doi: 10.1002/msj.20160.

Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Curr Opin Investig Drugs. 2010 Jan;11(1):80-91.

Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Mol Neurodegener. 2009 Dec 17;4:51. doi: 10.1186/1750-1326-4-51.

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866.

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Neurology. 2009 Dec 15;73(24):2061-70. doi: 10.1212/WNL.0b013e3181c67808. Epub 2009 Nov 18.

Homotaurine: a failed drug for Alzheimer's disease and now a nutraceutical for memory protection.

Am J Health Syst Pharm. 2009 Nov 1;66(21):1950-3. doi: 10.2146/ajhp080576.

Abeta species removal after abeta42 immunization.

J Neuropathol Exp Neurol. 2006 Nov;65(11):1040-8. doi: 10.1097/01.jnen.0000240466.10758.ce.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验